Anti-cyclic citrullinated peptides positivity rate in patients with familial Mediterranean fever.

OBJECTIVES To investigate the prevalence and levels of anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with familial Mediterranean fever (FMF) with and without arthritis. METHODS Eighty-three patients with FMF and 43 healthy controls were included in the study. Thirty seven FMF patients had a history of arthritis, and 46 patients did not. Serum antibodies directed to the anti-CCP were assessed with a commercial enzyme-linked immunosorbent assay (ELISA) kit. Values <20U were considered negative, between 20 and 39U low, 40-99U moderate, and >100U high positive. RESULTS Positivity rate of anti-CCP in the whole FMF group (14.5%) was three-fold higher than the control group (4.7%). However, the difference failed to achieve a statistically significant level (p=0.09). Anti-CCP levels were 21±30.1 in patients with arthritis and 13.1±10.3 in the non arthritic group (p<0.05). Anti-CCP positivity rates were 10/37 (27%) in patients with arthritis and 2/46 (4.3%) in patients without arthritis (p<0.005). Five FMF patients with arthritis (13.5%) had moderate-high anti-CCP levels (>40U/ml). Anti-CCP levels were between 20-39U/ ml in 2FMF patients without arthritis and in 2 healthy controls. Anti-CCP positivity rate is higher in FMF patients with arthritis (27%) than healthy controls (4.7%) (p<0.005). CONCLUSIONS Anti-CCP prevalence is higher in FMF patients with arthritis than without arthritis, and that a significant proportion of FMF patients with arthritis (13.5%) had moderate-high titers of anti-CCP. Therefore, anti-CCP antibodies may not be a reliable indicator to differentiate between FMF arthritis and rheumatoid arthritis.

[1]  H. Uzkeser,et al.  Anti-cyclic citrullinated peptide antibodies are not associated with familial Mediterranean fever. , 2010, Journal of back and musculoskeletal rehabilitation.

[2]  E. Lee,et al.  The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis , 2011, Rheumatology International.

[3]  E. Akbal,et al.  Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia , 2010, Rheumatology International.

[4]  M. Keleş,et al.  Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever , 2010, Rheumatology International.

[5]  Y. Qing,et al.  The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus , 2009, Lupus.

[6]  K. N. Verpoort.  Anti-citrullinated peptide antibodies in rheumatoid arthritis and undifferentiated arthritis , 2008 .

[7]  E. Ben-Chetrit,et al.  Non-response to colchicine in FMF--definition, causes and suggested solutions. , 2008, Clinical and experimental rheumatology.

[8]  M. Galeazzi,et al.  Saturday night fever: bizarre recurrence of fever attacks in a patient carrying a mutation in both the MEFV and TNFRSF1A genes. , 2008, Clinical and experimental rheumatology.

[9]  J. Cabiedes,et al.  Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy , 2008, Lupus.

[10]  E. Génin,et al.  Familial Mediterranean Fever In Lebanon: Founder Effects For Different MEFV Mutations , 2007, Annals of human genetics.

[11]  D. M. van der Heijde,et al.  High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study , 2007, Annals of the rheumatic diseases.

[12]  F. Sutterwala,et al.  Autoinflammatory syndromes and infections: pathogenetic and clinical implications. , 2008, Clinical and experimental rheumatology.

[13]  A. Işık,et al.  Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease. , 2007, The Tohoku journal of experimental medicine.

[14]  M. Lidar,et al.  Familial Mediterranean fever: clinical, molecular and management advancements. , 2007, The Netherlands journal of medicine.

[15]  W. Venrooij,et al.  Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. , 2006, Rheumatology.

[16]  M. Inanç,et al.  Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis , 2006, Clinical Rheumatology.

[17]  R. Caporali,et al.  Antibodies to cyclic citrullinated peptides in psoriatic arthritis. , 2005, The Journal of rheumatology.

[18]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[19]  E. Atalar,et al.  Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis. , 2003, The Journal of rheumatology.

[20]  M. Dougados,et al.  Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage , 2003, Annals of the rheumatic diseases.

[21]  M. Tekin,et al.  Arthritis in children with familial Mediterranean fever , 2002, Rheumatology International.

[22]  R. Hajj-Ali,et al.  Arthritis in familial Mediterranean fever , 2001, Rheumatology International.

[23]  D. Zemer,et al.  Criteria for the diagnosis of familial Mediterranean fever. , 1997, Arthritis and rheumatism.

[24]  H. A. Majeed,et al.  The clinical patterns of arthritis in children with familial Mediterranean fever. , 1997, QJM : monthly journal of the Association of Physicians.

[25]  M. Pras,et al.  Protracted arthritis in familial Mediterranean fever. , 1977, Rheumatology and rehabilitation.

[26]  F. Fernández-Nogués,et al.  [Familial, mediterranean fever]. , 1977, Revista clinica espanola.

[27]  E. Sohar,et al.  FAMILIAL MEDITERRANEAN FEVER , 1959, Definitions.